Keeping Muscle on GLP-1 Drugs: What the Evidence Supports

Weight loss on GLP-1 drugs is rarely only fat. Some of what leaves the scale is lean mass, and a flurry of 2026 papers asks how much can be kept and how. This article sticks to what the main sources actually say, and marks where they stop.

How much lean mass goes with the weight

The best quantified answer comes from a network meta analysis in Metabolism that pooled 22 randomized trials with 2,258 participants. GLP-1 receptor agonists lowered body weight by 3.55 kg on average against control, fat mass by 2.95 kg and lean mass by 0.86 kg. The authors put lean mass at about 25 percent of the total weight lost. Measured as a percentage of body weight, lean mass was not significantly changed.

The American Diabetes Association gives a wider range in a 2025 press release: lean body mass can account for up to 15 to 40 percent of total weight loss on GLP-1 therapies. The two figures are consistent in spirit but not identical, because they describe different groups of studies and methods.

The same meta analysis found differences by drug. Liraglutide was the only agent to reduce weight significantly without significantly reducing lean mass, while tirzepatide 15 mg and semaglutide 2.4 mg gave the biggest weight and fat loss and were among the least effective at preserving lean mass. That is a pattern across trials, not a head to head comparison, and bigger weight loss naturally leaves more room for lean mass to fall.

What the 2026 consensus recommends

A consensus statement from three European groups (EASO, EFAD and ECPO), published in The Lancet Diabetes and Endocrinology in 2026, covers nutrition, physical function and psychological aspects of incretin based treatment. According to its summary, it reviews protein targets during weight loss, dietary quality and ways to limit gastrointestinal side effects. It also describes practical approaches to support fat free mass and physical function, including adequate protein intake and progressive resistance exercise.

A separate 2026 review in Diabetes, Obesity and Metabolism reaches a similar place. It calls individualized protein intake, progressive resistance exercise, management of gastrointestinal side effects and functional monitoring reasonable strategies, and it adds an important caution: studies showing that resistance training prevents muscle loss specifically during GLP-1 therapy remain limited, and the best type, intensity and duration are not settled.

Why protein is part of the story

These drugs work largely by lowering appetite, which can lower protein intake along with calories. A 2026 review in Advances in Therapy raises that point for older adults, who already respond less to protein and exercise. The common advice follows from the logic, but logic is not the same as a trial result for each recommendation.

Small studies point the same way without settling it. One 2026 pilot of 11 adults on semaglutide added eight weeks of resistance training after four weeks of medication alone. Fat mass fell by 3.355 kg during the training phase and fat free mass showed a non significant rise of 1.1 kg. With so few participants and no control group on the drug without training, it is a hint about feasibility rather than evidence of an effect size.

A second 2026 report, an uncontrolled program combining tirzepatide, testosterone therapy and coaching on resistance exercise and protein, saw muscle mass and grip strength rise over twelve months. Its own authors say the design prevents crediting any single component. Taken together, such reports explain why reviewers call the area promising but under tested.

Drugs aimed at muscle, and what is not yet shown

The ADA release also reports the BELIEVE phase 2b trial, which randomized 507 adults to semaglutide, bimagrumab or both. With the combination, 92.8 percent of weight loss came from fat mass, against 71.8 percent with semaglutide alone. These results were presented at a conference and are not yet a full peer reviewed paper in this source; they measure body composition, not whether people could do more. For a closer look at that class, see the myostatin antibody trials.

Questions worth asking a clinician

Which measure matters for the person: lean mass on a scan, grip strength, or the ability to climb stairs? Is protein intake actually being tracked while appetite is low? Is resistance training realistic given age, joints or time, and who can supervise it? These are questions for a doctor or dietitian, not conclusions from the studies above, and none of this is medical advice. The next checkable step is the registered protocol for a systematic review of adjunct exercise and nutrition strategies on the Open Science Framework, dated September 2026, which aims to test the question directly.